At the news
? BULLISHIMPACT 6/10 8-K filed Nov 2, 2026 at 16:05 ET
Travere Therapeutics reported Q3 2026 FILSPARI net product sales of $200.2M, up 120% YoY, and total revenue of $224.6M, well above the $195.3M consensus. However, GAAP net loss was $52.3M ($0.55/share) versus net income of $25.7M a year ago, driven by a $113.1M IPRD charge for the civorebrutinib license and higher R&D and SG&A spending. The company ended the quarter with $471.8M in cash and securities.
- FILSPARI net product sales of $200.2M in Q3 2026, up 120% year-over-year from $90.9M
- Total revenue of $224.6M, up from $164.9M in Q3 2025
- 1,932 new patient start forms (PSFs) received during Q3 2026
- GAAP net loss of $52.3M ($0.55 per share) vs net income of $25.7M ($0.29 per share) in Q3 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access